Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Pharmas Market Video Gallery
Discussing whether a new $487M investment from the government will help speed up the production of the most important va...
Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are...
PHARMA WATCH LIST
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

SPECIAL REPORT


Current DateTime: 09:29:28 25 Nov 2009
LinksList Documentid: 32984624

PHARMA'S MARKET VIDEO

» More

Current DateTime: 09:29:28 25 Nov 2009
LinksList Documentid: 31171988
Expiration DateTime: 11/25/2009 9:30:08 AM

RSS FEED

» Help

Current DateTime: 09:29:29 25 Nov 2009
LinksList Documentid: 31171995
powered by digg

Pharma's Market

Text Size
Jul.23
12:18 PM ET

On the Pfizer [PFE  Loading...      ()   ] earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."

As a Pfizer PR person pointed out in an email following my earnings story on "Squawk on the Street" this morning, worldwide Viagra sales in the second quarter were up 21 percent versus the same period last year, U.S. Viagra revenue was up a whopping 41 percent and international sales of the little blue pill rose nine percent. But I like to look behind the numbers, oftentimes much to the consternation of the above-mentioned PR person and his/her colleagues at PFE and at other drug companies.

And I think I found an interesting trend, if you can call it that. I went back through Pfizer's quarterly earnings reports over the past year. In the second quarter of 2007 U.S. Viagra sales were $142 million. They jumped to $208 million in Q3-'07, remained flat in Q4, and then shot up again in the first quarter of this year to $220 million. But in the second quarter--and I'm trying so hard to avoid obvious puns and plays on words--U.S. Viagra revenue fell to $199 million. Which brings me back to Kindler's opening statement about the economy.

I wonder if the weak American economy is causing men to cut out Viagra from their budgets. Or maybe more of them are cutting their pills in half. I know that urologists and the companies that make the erectile dysfunction drugs--PFE, Eli Lilly [LLY  Loading...      ()   ], GlaxoSmithKline [GSK  Loading...      ()   ], Schering-Plough [SGP  Loading...      ()   ] and Bayer [BAY  Loading...      ()   ] --are quick to say that impotence can be a sign of much more serious health problems and that the drugs shouldn't be viewed as lifestyle or recreational products, but that's how most people I know think of them. At drugstore.com 30 25mg pills cost nearly 400 bucks and that's supposedly with a 20 percent discount!

We'll find out if I'm onto something, perhaps, when LLY reports its earnings tomorrow morning and whether sales of Cialis are also down or maybe it's simply stealing market share from Viagra.

Questions?  Comments? 

© 2009 CNBC, Inc. All Rights Reserved

Tools:
PrintEmailAdd This share icon
Next Post
  • digg share
ADD COMMENTS
Remaining characters


Current DateTime: 05:21:41 25 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 08:51:31 25 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 02:05:47 25 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 08:49:59 25 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters